Harnessing genomics to improve outcomes for women with cancer in India: key priorities for research

Abstract

Cumulatively, breast, cervical, ovarian, and uterine cancer account for more than 70% of cancers in women in India. Distinct differences in the clinical presentation of women with cancer suggest underlying differences in cancer biology and genetics. The peak age of onset of breast and ovarian cancer appears to be a decade earlier in India (age 45-50 years) than in high-income countries (age >60 years). Understanding these differences through research to develop diagnosis, screening, prevention, and treatment frameworks that ar e specific to the Indian population are critical and essential to improving women's health in India. Since the sequencing of the human genome in 2001, applications of advanced technologies, such as massively parallel sequencing, have transformed the understanding of the genetic and environmental drivers of cancer. How can advanced technologies be harnessed to provide health-care solutions at a scale and to a budget suitable for a country of 1·2 billion people? What research programmes are necessary to answer questions specific to India, and to build capacity for innovative solutions using these technologies? In order to answer these questions, we convened a workshop with key stakeholders to address these issues. In this Series paper, we highlight challenges in tackling the growing cancer burden in India, discuss ongoing genomics research and developments in infrastructure, and suggest key priorities for future research in cancer in India.

In search of the altering salivary proteome in metastatic breast and ovarian cancers

“…5 In India, the peak age (age 45-50 years) of onset of breast and ovarian cancers occurs 10 years earlier, compared to those reported in developed countries. 6 Cancer metastasis to distant organs and their late-stage detection are the major cause of mortality in females with breast and ovarian cancers. Metastasis of primary tumors by local invasion into surrounding tissue, and subsequent progression to a distant site where it starts forming new tumor colonies have been observed in many cases, and involve a series of intruding events known as an invasion metastasis cascade.…”

QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study

“…However, on literature review, no clinical trials were encountered, and the limited number of studies lack enough potential to be termed as efficacious for acceptable treatment outcome for postchemotherapeutic drug-induced alopecia. 26 …”

Cancer research in India: Challenges & opportunities

“…This includes exposing graduate and postgraduate medical students, community physicians and medical college teachers about translation clinical research, and developing adequate infrastructure. Indian pharmaceutical industry has made phenomenal growth in the field of generic molecules; they need to invest in the development of new molecules and India centric cancer research1415.…”